Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegol-Sihematide vs ESPO for Anemia in Dialysis Patients
NCT03902691Phase 3Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2019
- Primary completion
- Feb 2021
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peglmolesatide in anemia (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Mean change from baseline hemoglobin level to mean level during evaluation period. Started May 2019; status: completed.
02
Drugs
peglmolesatide
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03902691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902691.